Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2575

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2575
---
 ●
    the
    outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, and other
    comparable foreign regulatory authorities;

    ●
    the
    cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;

    ●
    the
    cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our
    product candidates;

    ●
    the
    extent to which we enter into additional collaboration agreements with regard to product discovery or acquire or in-license products
    or technologies;

    ●
    the
    effect of competing technological and market developments;

    ●
    the
    cost and timing of completion of commercial-scale outsourced manufacturing activities;

    ●
    the
    cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory
    approval in regions where we choose to commercialize our products on our own; 

    ●
    the
    timing and amounts of any milestone or royalty payments we may be required to make or may be entitled to receive under license agreements;

    ●
    the
    costs of building out our infrastructure including hiring additional clinical, quality control and manufacturing personnel;

    ●
    the
    costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for
    any of our product candidates for which we receive marketing approval;

    ●
    the
    revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

    ●
    the
    costs of operating as a public company; and

    ●
    the
    extent to which we acquire or in-license other product candidates and technologies.

We
cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue
to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or
private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution
arrangements. This additional funding may not be sufficient for us to fund any of our products through regulatory approval.

72

To
the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock,
your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and